For those with thyroid disorders with ocular involvement, with exophthalmos (bulging eyes), there is good news, a new treatment, Tocilzumab, is getting very good results.
We know that in many cases the exophthalmos does not respond well to conventional treatment with corticosteroids and radiotherapy or decompressive surgery may not be indicated. In these cases we have a new treatment, Tocilzumab, which is showing very good results. The global study is headed by Prof José Perez Moreiras, a good friend and a great specialist in orbit. For those who want to know more, you can read the article published in Diario Médico.
Thyroid exophthalmos with myositis of internal and external muscles
Ocular proptosis in a patient with hyperthyroidism
Caiber start a Phase III trial for thyroid orbitopathy.
Thyroid orbitopathy is a rare autoimmune disorder that affects about 8,500 people each year, of which 7,000 are women. It is characterized by inflammation of the tissues around the eyes and causes symptoms such as eye irritation, lacrimation, photophobia, blurred vision, feeling of pressure in the orbit and ocular protrusion. It is associated with thyroid gland disorders. In fact, about 15 percent of patients with hyperthyroidism suffer orbitopathy. Treatment options are limited. The current is mainly based on the administration of high doses of corticosteroids and, in severe cases, decompressed surgery. To test new therapies for this condition, Caiber (Clinical Trials Spanish Platform) has launched a clinical trial to evaluate Phase III in 32 patients, the efficacy and safety of the administration of the monoclonal antibody tocilizumab in patients with thyroid orbitopathy, moderate or severe, who have not responded to treatment with corticosteroides “. There are reasons to believe that inhibition of interleukin-6 (IL-6) with tocilizumab may be effective in patients with this disease,” said Juan Jesús Gómez Kingdom, Department of Rheumatology, clinical Hospital of Santiago de Compostela, and one of the coordinators of the clinical trial. “IL-6 is a highly potent mediator of inflammatory responses is expressed in the periorbital inflamed tissue. Furthermore, the inflammation that occurs in the periorbital tissue is similar to that of other diseases such as rheumatoid arthritis, where the use of tocilizumab has been effective. “